EATG » Hepatitis

Hepatitis

High prices of DAAs mean there’s been little progress towards achieving WHO target of eliminating HCV by 2030

Only a handful of countries are on course to achieve the World Health Organization (WHO) target of eliminating hepatitis C virus (HCV) as a major public health concern by 2030,…

FDA grants orphan drug designation to Lambda for HDV

FDA granted orphan drug designation to Eiger BioPharmaceuticals for its pegylated interferon lambda 1a, known as Lambda, to treat chronic hepatitis delta virus infection, according to a press release. Lambda,…

Women with HCV face low ovarian reserve, infertility, miscarriage

Women of child-bearing age with hepatitis C showed early signs of menopause, putting them at greater risk for infertility, gestational diabetes and miscarriage, according to a recently published study. Sustained…

HCV therapy low among HIV/HCV patients with alcohol dependence

Alcohol dependence presents a significant barrier to hepatitis C treatment among patients with HIV compared with non-alcohol substance dependence, according to a presentation at the International Symposium on Hepatitis Care…

Janssen to discontinue hepatitis C development program

Viral hepatitis research and development to focus on addressing significant unmet needs in chronic hepatitis B  CORK, Ireland, September 11, 2017 - Janssen Sciences Ireland UC (Janssen), today announced a strategic decision…

ContraVir receives HBV IND approval for tenofovir exalidex (TXL™) in the US

EDISON, N.J., Sept. 11, 2017 -- ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that the U.S. Food and…

HCV treatment found safe and effective in individuals with kidney disease

Highlights In patients with chronic kidney disease and Hepatitis C virus infection, sofosbuvir-based direct-acting antiviral therapy was safe and effective. Patients with stage 3 kidney disease who were cured of…

Injection drug users with HCV in Scotland lack awareness of DAA efficacy

Most people who inject drugs were not aware of currently available, highly effective hepatitis C treatments, according results of a national survey in Scotland presented at the International Symposium on…

Among injection drug users in San Francisco, young adults at highest risk for HCV

Adult injection drug users aged 30 years or younger are both at the highest risk for acquiring hepatitis C and transmitting HCV, according to a presentation at the International Symposium…

People who use drugs require prioritization, not exclusion, in HCV elimination

An international conference bringing together hepatitis C experts from around the world is today calling for strategies to prioritise people who use drugs, saying hepatitis C elimination is impossible without…